eldecalcitol Report issue

Small molecule Experimental
AACT DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Eldecalcitol is a drug used in Japan for the treatment of osteoporosis. It is an analog of vitamin D. Osteoporosis is a common bone disease among the older generation, with an estimated prevalence of over 200 million people. This condition often results in bone fractures due to abnormally low bone mass density, and is a leading cause of disability, especially among developed countries with longer average life spans. Osteoporosis is more common in women than with men.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

1α,25-dihydroxy-2β-(3-hydroxypropoxy)cholecalciferol | 20-epi-1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin d3 | 20-epi-ed-71 | 20-epi-eldecalcitol | 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin d3 | 2-(3-hydroxypropoxy)calcitriol | 9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol, 2-(3-hydroxypropoxy)-, (1alpha,2beta,3beta,5z,7e)- | ed 71 | ed-71 | eldecalcitol

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Osteoporosis

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Osteoporosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue